Acadia Pharmaceuticals Inc. (ACAD) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Acadia Pharmaceuticals’s revenue went from $17M in fiscal 2016 to $1.1B in fiscal 2025, growth of about 58.1% a year.
Net income in fiscal 2025 was $391M, a net margin of 36.5%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $1.2B and net income $362M.
Free cash flow was $105M in fiscal 2025 and positive in 3 of the 10 years shown.
The diluted share count fell 100% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.1B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M |
| Gross profit | $1.1B | $983M | $876M | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M |
| Operating income | $122M | $105M | $231M | -$73M | -$224M | -$170M | -$287M | -$247M | -$247M | -$292M | -$273M |
| Net income | $362M | $391M | $226M | -$61M | -$216M | -$168M | -$282M | -$235M | -$245M | -$289M | -$271M |
| EPS (diluted) | $2.12 | $2.30 | $1.36 | $-0.37 | $-1.34 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| R&D | $319M | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M |
| Revenue growth | — | +11.9% | +31.9% | +40.5% | +6.8% | +9.6% | +30.3% | +51.5% | +79.2% | +620.7% | +28311.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $98M | $110M | $158M | $17M | -$114M | -$126M | -$136M | -$151M | -$167M | -$218M | -$208M |
| Capital spending | -$16M | -$5M | -$523000 | -$50000 | $0 | -$1M | -$8M | -$1M | -$2M | -$812000 | -$2M |
| Free cash flow | $82M | $105M | $157M | $17M | -$114M | -$127M | -$144M | -$152M | -$170M | -$219M | -$210M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $62M | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $820M | $756M | $439M | $417M | $521M | $632M | $697M | $474M | $341M | $529M |
| Debt | — | $52M | $52M | $57M | $62M | $64M | $50M | $10M | — | — | — |
| Equity | — | $1.2B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M |
| Total assets | — | $1.6B | $1.2B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M |
| Shares (diluted) | 175M | 170M | 166M | 164M | 162M | 160M | 157M | 147.20B | 126.58B | 122.60B | 115.86B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 90.5% | 91.7% | 91.5% | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% |
| Operating margin | 10.2% | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% |
| Net margin | 30.1% | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% |
| FCF margin | 6.8% | 9.8% | 16.4% | 2.3% | -22.1% | -26.2% | -32.5% | -44.9% | -75.8% | -175.0% | -1211.2% |
| ROIC | — | 6.5% | 25.8% | -11.9% | -38.2% | -22.2% | -33.5% | -27.5% | -40.8% | -68.9% | -41.6% |
| ROE | — | 31.9% | 30.9% | -14.2% | -53.9% | -31.0% | -44.9% | -33.7% | -51.2% | -86.3% | -52.3% |
Frequently asked questions
What is Acadia Pharmaceuticals’s annual revenue?
$1.1B in fiscal 2025 and $1.2B over the twelve months to September 30, 2026.
How much profit does Acadia Pharmaceuticals make?
Net income was $391M in fiscal 2025 (net margin 36.5%).
Is Acadia Pharmaceuticals’s revenue growing?
Yes: revenue rose 11.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.